Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Barbara Rybus-Kalinowska is active.

Publication


Featured researches published by Barbara Rybus-Kalinowska.


Journal of Viral Hepatitis | 2010

Visfatin serum levels in chronic hepatitis C patients

Michał Kukla; Krystyna Żwirska-Korczala; Andrzej Gabriel; Marek Waluga; I. Warakomska; Agnieszka Berdowska; Barbara Rybus-Kalinowska; Mariusz Kalinowski; E. Janczewska-Kazek; E. Woźniak-Grygiel; W. Kryczka

Summary.  Visfatin is a new adipokine involved in several processes. The data concerning visfatin in chronic hepatitis C (CHC) is small. To assess visfatin serum concentration and to study its association with biochemical and morphological features in CHC. Seventy nonobese patients with CHC (Group 1) confirmed by the presence of serum hepatitis C virus (HCV)‐RNA and 20 healthy volunteers (Group 2), similar in age and BMI with normal fasting glucose and lipid profile were included. Visfatin was significantly increased in Group 1 compared with Group 2 (55.6 ± 23.1 vs 23.7 ± 3.8 ng/mL; P < 0.001). Visfatin was negatively associated with necro‐inflammatory activity grade (r = −0.36; P = 0.007). The lowest levels were found in patients with the most advanced inflammation: grades 3–4 – 46.8 ± 17.1, grade 2 – 52.6 ± 18.4 and grade 1 – 75.2 ± 27.6 ng/mL; P = 0.017. A significant difference was also shown comparing patients with minimal inflammatory activity to the rest of the cohort (P = 0.009). Visfatin receiver operating characteristic curve analysis for different necro‐inflammatory activity – grade 1 vs grades 3–4 with area under the curve 0.81 indicated a good discriminant power for differentiation of moderate/severe inflammation, with the cut‐off set at 57.6 ng/mL (sensitivity 75%, specificity 90%, positive predictive value 0.90, negative predictive value 0.75). Serum visfatin concentration increases significantly in CHC patients. These findings suggest that visfatin is important in the pathogenesis of the inflammatory process in CHC. Visfatin may play a dual role as a pro‐inflammatory or/and protective factor. The measurement of visfatin serum concentration may serve as an additional tool in distinguishing more advanced grades of the necro‐inflammatory activity.


Therapeutic Advances in Gastroenterology | 2009

sPECAM-1 and sVCAM-1: role in pathogenesis and diagnosis of chronic hepatitis C and association with response to antiviral therapy:

Michał Kukla; Krystyna Zwirska-Korczala; Andrzej Gabriel; Ewa Janczewska-Kazek; Agnieszka Berdowska; Andrzej Wiczkowski; Barbara Rybus-Kalinowska; Mariusz Kalinowski; Adam Ziółkowski; Elzbieta Wozniak-Grygiel; Marek Waluga; Blazej Nowak

Aim: To analyze the relationship between pretreatment clinical or histological features and the levels of soluble platelet-endothelial cell adhesion molecule-1 (sPECAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1), to determine their serum concentration in responders and nonresponders, to evaluate the behavior under antiviral therapy, to explain their relationship in response to therapy and to assess the association between these two molecules in chronic hepatitis C (CHC). Methods: The study analyzed 65 CHC patients, including 50 patients (Group 1) with marked fibrosis treated with peginterferon plus ribavirin, 15 patients without fibrosis (Group 2) and 13 healthy volunteers (the control group, Group 3). sPECAM-1 and sVCAM-1 levels were assessed by an immunoenzymatic method (ELISA) before and after therapy. Results: sVCAM-1 and sPECAM-1 serum concentrations increased significantly in CHC patients (p<0.001). sPECAM-1 levels corresponded to inflammatory grade (p = 0.03) and fibrosis stage (p = 0.01). sVCAM-1 increased only in advanced fibrosis. After therapy, sPECAM-1 levels decreased significantly (p<0.001) with no difference between responders and nonresponders. sPECAM-1 correlated positively with inflammatory activity (p = 0.02), fibrosis stage (p<0.001), sVCAM-1 (r = 0.56, p<0.001) and alanine aminotransferase activity (r = 0.30, p = 0.05). Receiver operating characteristic curve analysis showed a good discriminant power of serum sPECAM-1 concentrations for detection of liver fibrosis — stage 0 versus stage 1—3, AUC 0.81; cut-off 221.0 ng/ml and a fair discriminant power for distinguishing bridging fibrosis, AUC 0.78; cut-off 237.1 ng/ml. Conclusions: Hepatitis C virus (HCV) infection results in upregulation of sPECAM-1 and sVCAM-1. sPECAM-1 levels are related to necroinflammatory activity and may also identify patients with advanced fibrosis. The sPECAM-1 value was decreased by therapy but its measurement cannot predict therapy outcome and confirm HCV persistence. sPECAM-1 may influence VCAM-1 expression.


Annales Academiae Medicae Silesiensis | 2016

Histamine in cheeses – a potential danger?

Katarzyna Chojnacka; Karolina Jasikowska; Barbara Rybus-Kalinowska; Jerzy Jochem; Elżbieta Grochowska-Niedworok

Cheeses are complex products with high content of fat, protein and other inorganic compounds. It is a food product, which may differ because of their origin, the manufacturing conditions, the microbiological flora and enzymatic activity. All these parameters can affect the efficiency analysis, which in turn may constitute an impediment to the determination of the cheese histamine concentration. The main factors influencing the formation of biogenic amines, including Received: 06.06.2016 Revised: 12.06.2016 Accepted: 13.06.2016 Published online: 30.12.2016 Adres do korespondencji: Mgr Katarzyna Chojnacka, Zakład Etyki i Deontologii Medycznej, Wydział Zdrowia Publicznego, Śląski Uniwersytet Medyczny w Katowicach, ul. Piekarska 18, 41-902 Bytom, e-mail: [email protected] Copyright


Polskie Archiwum Medycyny Wewnetrznej-polish Archives of Internal Medicine | 2003

[Assessment of blood superoxide dismutase, glutathione peroxidase activity and malondialdehyde concentration as oxidation status parameters in obese women].

Krystyna Zwirska-Korczala; Jerzy Jochem; Barbara Rybus-Kalinowska; Renata Polaniak; Ewa Birkner


Polskie Archiwum Medycyny Wewnetrznej-polish Archives of Internal Medicine | 2008

Activity of antioxidative enzymes and concentration of malondialdehyde as oxidative status markers in women with newly diagnosed Graves-Basedow disease and after thiamazole therapy leading to euthyroidism.

Barbara Rybus-Kalinowska; Krystyna Zwirska-Korczala; Kalinowski M; Michał Kukla; Ewa Birkner; Jerzy Jochem


Polish Journal of Pharmacology | 2002

Influence of SKF 91488, histamine N-methyltransferase inhibitor, on the central cardiovascular regulation during controlled, stepwise hemorrhagic hypotension in rats.

Jerzy Jochem; Krystyna Zwirska-Korczala; Barbara Rybus-Kalinowska; Julia Jagodzinska; Ilona Korzonek-Szlacheta


Endokrynologia Polska | 2009

Activity of antioxidative enzymes and concentration of malondialdehyde as oxidative status markers in women with non-autoimmunological subclinical hyperthyroidism

Barbara Rybus-Kalinowska; Krystyna Żwirska-Korczala; Mariusz Kalinowski; Michał Kukla; Ewa Birkner; Jerzy Jochem


Pediatria i Medycyna Rodzinna | 2018

Grade 4 hypertensive retinopathy in a 13-year-old girl as a serious complication of nephrogenic hypertension

Barbara Rybus-Kalinowska; Bogna Teodorowicz-Rachuba; Mariusz Kalinowski; Beata Łabuz-Roszak; Brygida Adamek; Lidia Hyla-Klekot


Pediatria i Medycyna Rodzinna | 2017

Retinopathy of prematurity – etiopathogenesis and treatment

Barbara Rybus-Kalinowska; Sławomir Kwiatkowski; Katarzyna Chojnacka; Jerzy Jochem


Annales Academiae Medicae Silesiensis | 2016

Histamina w serach – potencjalne zagrożenie?

Katarzyna Chojnacka; Karolina Jasikowska; Barbara Rybus-Kalinowska; Jerzy Jochem; Elżbieta Grochowska-Niedworok

Collaboration


Dive into the Barbara Rybus-Kalinowska's collaboration.

Top Co-Authors

Avatar

Jerzy Jochem

Medical University of Silesia

View shared research outputs
Top Co-Authors

Avatar

Mariusz Kalinowski

Medical University of Silesia

View shared research outputs
Top Co-Authors

Avatar

Ewa Birkner

Medical University of Silesia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Michał Kukla

Medical University of Silesia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Andrzej Gabriel

Medical University of Silesia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Marek Waluga

Medical University of Silesia

View shared research outputs
Top Co-Authors

Avatar

Adam Ziółkowski

Medical University of Silesia

View shared research outputs
Researchain Logo
Decentralizing Knowledge